Indian pharma eyes US generic gold rush

News | 27 June 2012

• Print This

In just the last six months, Ranbaxy has mopped up a cool $600 million (Rs 3417 crore) in revenue from the sale of generic Lipitor. Between 2012 and 2015, ...

Click on the link to read the full article at Business Standard
(This link will open in a new window)